Sintilimab plus cetuximab and chemo for first-line advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be advanced (stage IV) and cannot be removed by surgery or has come back after treatment.
- You cannot have had any prior chemotherapy or targeted therapy for advanced cancer, or if you had adjuvant chemo, it must be at least 6 months ago.
- Your tumor must be tested and found to have no mutations in RAS or BRAF genes (wild-type), and must have PD-L1 CPS ≥1, TPS ≥1%, or CD8+ TILs ≥2%.
- You must be in good general health (able to carry out daily activities) and have adequate organ function (kidney, liver, bone marrow).
- You cannot have certain autoimmune diseases, active infections like hepatitis B or C, or a history of other cancers in the last 5 years (except cured skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.